These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7423193)

  • 1. Genotoxicity of the antihypertensive drugs hydralazine and dihydralazine.
    Williams GM; Mazue G; McQueen CA; Shimada T
    Science; 1980 Oct; 210(4467):329-30. PubMed ID: 7423193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo and in vitro genotoxicity of three antihypertensive hydrazine derivatives (hydralazine, dihydralazine, and endralazine).
    de Flora S; Zanacchi P; Bennicelli C; Camoirano A; Cavanna M; Sciabà L; Cajelli E; Faggin P; Brambilla G
    Environ Mutagen; 1982; 4(5):605-19. PubMed ID: 7140679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the mutagenic activity of hydralazine and dihydralazine in Salmonella typhimurium strains differing in expression of antioxidant genes.
    Chłopkiewicz B
    Toxicol Lett; 1999 Nov; 110(3):203-7. PubMed ID: 10597029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of metabolic activation on the induction of micronuclei by antihypertensive drugs in L929 cells.
    Chłopkiewicz B
    Arch Toxicol; 2001 Feb; 74(12):794-8. PubMed ID: 11305783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotoxicity of hydrazino-phtalazine antihypertensive drugs assessed by an in vitro micronucleus assay.
    Chłopkiewicz B
    Acta Pol Pharm; 1996; 53(5):361-4. PubMed ID: 9415211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic effects of binazine and hydralazine in vitro and in vivo.
    Chłopkiewicz B; Ejchart A; Marczewska J
    Acta Pol Pharm; 1995; 52(1):31-3. PubMed ID: 8960236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA-damaging activity in vivo and bacterial mutagenicity of sixteen hydrazine derivatives as related quantitatively to their carcinogenicity.
    Parodi S; De Flora S; Cavanna M; Pino A; Robbiano L; Bennicelli C; Brambilla G
    Cancer Res; 1981 Apr; 41(4):1469-82. PubMed ID: 7214329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutagenicity of hydralazine in mammalian cells and bacteria.
    McQueen CA; Way BM; Queener SM
    Toxicol Appl Pharmacol; 1993 Jan; 118(1):135-8. PubMed ID: 8430421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic toxicity of several antihypertensive drugs possessing a hydrazine group.
    Kitamura J; Mori H; Sugie S; Kawai K
    Res Commun Chem Pathol Pharmacol; 1985 Sep; 49(3):415-22. PubMed ID: 4059657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the mechanism of mutagenicity and genotoxicity induced by dihydralazine.
    Chłopkiewicz B; Ejchart A; Marczewska J
    Acta Biochim Pol; 1995; 42(3):291-5. PubMed ID: 8588478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutagenicity of B(a)P in the presence of some hydralazine derivatives.
    Gasiorowski K; Szyba K; Sawicka J; Gulanowski B
    Pol J Occup Med Environ Health; 1993; 6(4):383-9. PubMed ID: 8019200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylation and its role in the mutagenicity of the antihypertensive agent hydralazine.
    Lemke LE; McQueen CA
    Drug Metab Dispos; 1995 May; 23(5):559-65. PubMed ID: 7587931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assay of 855 test chemicals in ten tester strains using a new modification of the Ames test for bacterial mutagens.
    McMahon RE; Cline JC; Thompson CZ
    Cancer Res; 1979 Mar; 39(3):682-93. PubMed ID: 371791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo testing of hydralazine genotoxicity.
    Martelli A; Allavena A; Campart GB; Canonero R; Ghia M; Mattioli F; Mereto E; Robbiano L; Brambilla G
    J Pharmacol Exp Ther; 1995 Apr; 273(1):113-20. PubMed ID: 7714756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reliability of the hepatocyte primary culture/DNA repair test in testing of coded carcinogens and noncarcinogens.
    Williams GM; Laspia MF; Dunkel VC
    Mutat Res; 1982 Oct; 97(5):359-70. PubMed ID: 7144803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydralazine therapy and acetylator phenotype.
    Iisalo E; Laine T; Lehtonen A; Sellman R
    Int J Clin Pharmacol Biopharm; 1979 Mar; 17(3):119-24. PubMed ID: 429082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma concentrations and pharmacokinetics of dihydralazine after single oral doses to human subjects.
    Waller AR; Chasseaud LF; Taylor T; Darragh A; O'Kelly DA
    Biopharm Drug Dispos; 1979; 1(2):59-64. PubMed ID: 552862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro mutagenicity assays of chemical carcinogens and related compounds with Salmonella typhimurium.
    Simmon VF
    J Natl Cancer Inst; 1979 Apr; 62(4):893-9. PubMed ID: 372657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotoxicity of a variety of mycotoxins in the hepatocyte primary culture/DNA repair test using rat and mouse hepatocytes.
    Mori H; Kawai K; Ohbayashi F; Kuniyasu T; Yamazaki M; Hamasaki T; Williams GM
    Cancer Res; 1984 Jul; 44(7):2918-23. PubMed ID: 6722817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA damage and repair tests for the detection of genotoxic agents.
    Williams GM
    Food Addit Contam; 1984; 1(2):173-8. PubMed ID: 6536528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.